John Spencer - GeoVax Labs Independent Director
| GOVX Stock | USD 1.42 0.03 2.07% |
Director
Mr. John N. Spencer Jr., CPA is an Independent Director of GeoVax Labs Inc. Mr. Spencer is a certified public accountant and was a partner of Ernst Young LLP where he spent more than 38 years until he retired in 2000. Mr. Spencer also serves as a director of MRI Interventions, Inc., a medical device company, where he also chairs the audit committee and serves on the compensation committee. He served as the Temporary Chief Financial Officer of Applied Genetic Technologies Corporation from November 2013 until February 2014 while that company prepared its initial public offering. He also serves as a consultant to various companies primarily relating to financial accounting and reporting matters since 2006.
| Age | 76 |
| Tenure | 18 years |
| Professional Marks | MBA |
| Address | 1900 Lake Park Drive, Smyrna, GA, United States, 30080 |
| Phone | 678 384 7220 |
| Web | https://www.geovax.com |
GeoVax Labs Management Efficiency
The company has return on total asset (ROA) of (0.8227) % which means that it has lost $0.8227 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6047) %, meaning that it created substantial loss on money invested by shareholders. GeoVax Labs' management efficiency ratios could be used to measure how well GeoVax Labs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.94 in 2024. Return On Capital Employed is likely to rise to -4.41 in 2024. At this time, GeoVax Labs' Other Current Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.2 M in 2024, whereas Total Assets are likely to drop slightly above 4.9 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Adrian Montgomery | Acasti Pharma | N/A | |
| Folkert Kamphuis | Jaguar Animal Health | 57 | |
| Jeffrey Johnson | Jaguar Animal Health | 45 | |
| Jean Belanger | Acasti Pharma | N/A | |
| Richard Schottenfeld | Acasti Pharma | N/A | |
| Zhi Yang | Jaguar Animal Health | 61 | |
| Reed Tuckson | Acasti Pharma | 63 | |
| Kurt Graves | Pulmatrix | 47 | |
| Matthew Sherman | Pulmatrix | 61 | |
| Gregory Divis | Jaguar Animal Health | 50 | |
| Terrance McGuire | Pulmatrix | 61 | |
| JeanMarie Canan | Acasti Pharma | 57 | |
| Richard Conley | Pulmatrix | 63 | |
| Scott Rocklage | Pulmatrix | 60 | |
| Ari Azhir | Jaguar Animal Health | 69 | |
| Jiahao Qiu | Jaguar Animal Health | 31 | |
| Katherine Crewe | Acasti Pharma | N/A | |
| Akihisa Akao | Pulmatrix | 59 | |
| John Micek | Jaguar Animal Health | 64 | |
| Donald Olds | Acasti Pharma | 57 | |
| David MacNaughtan | Jaguar Animal Health | 50 | |
Management Performance
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.82 |
GeoVax Labs Leadership Team
Elected by the shareholders, the GeoVax Labs' board of directors comprises two types of representatives: GeoVax Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeoVax. The board's role is to monitor GeoVax Labs' management team and ensure that shareholders' interests are well served. GeoVax Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeoVax Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Sec | ||
| Jeffrey Welch, Head Operations | ||
| MD FACOG, Special Directors | ||
| Mark Reynolds, CFO, Corporate Secretary | ||
| David Dodd, Independent Chairman of the Board | ||
| Dean Kollintzas, Independent Director | ||
| Robert McNally, CEO and President and Director | ||
| John Niles, Head Operations | ||
| Mark Newman, Chief Officer | ||
| Mark CPA, CFO Secretary | ||
| Harriet Robinson, Co-Founder, Chief Scientific Officer and Director | ||
| John Sharkey, Vice Development | ||
| Thomas OBrien, Vice Compliance | ||
| Farshad Guirakhoo, Chief Scientific Officer | ||
| John Spencer, Independent Director | ||
| Randal Chase, Director | ||
| McKee MD, Chief Officer |
GeoVax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GeoVax Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.82 | ||||
| Current Valuation | (3.3 M) | ||||
| Shares Outstanding | 2.31 M | ||||
| Shares Owned By Insiders | 1.59 % | ||||
| Shares Owned By Institutions | 9.05 % | ||||
| Number Of Shares Shorted | 6.32 K | ||||
| Price To Earning | (1.25) X | ||||
| Price To Book | 0.64 X | ||||
| Price To Sales | 59.01 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GeoVax Labs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy GeoVax Stock please use our How to Invest in GeoVax Labs guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for GeoVax Stock analysis
When running GeoVax Labs' price analysis, check to measure GeoVax Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeoVax Labs is operating at the current time. Most of GeoVax Labs' value examination focuses on studying past and present price action to predict the probability of GeoVax Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeoVax Labs' price. Additionally, you may evaluate how the addition of GeoVax Labs to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is GeoVax Labs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GeoVax Labs. If investors know GeoVax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GeoVax Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.29) | Quarterly Revenue Growth (1.00) | Return On Assets (0.82) | Return On Equity (1.60) |
The market value of GeoVax Labs is measured differently than its book value, which is the value of GeoVax that is recorded on the company's balance sheet. Investors also form their own opinion of GeoVax Labs' value that differs from its market value or its book value, called intrinsic value, which is GeoVax Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GeoVax Labs' market value can be influenced by many factors that don't directly affect GeoVax Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GeoVax Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if GeoVax Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GeoVax Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.